PhRMA Statement on the White House's Great Healthcare Plan Announcement

WASHINGTON, D.C. (January 15, 2026) - Today, Alex Schriver, Senior Vice President of PhRMA's Public Affairs team, released the following statement in response to the White House's Great Healthcare Plan announcement:

"Voters are right to be angry about the affordability of health care. Skyrocketing premiums and increasing insurance denials are making it harder for patients to access the care they need. Holding insurance companies and PBMs accountable and letting patients buy medicines directly will significantly lower what patients pay.

"Imposing broad-based price controls does nothing to address insurance barriers and would instead threaten access to breakthrough treatments and undermine critical investments that strengthen the U.S. economy. The Trump administration has rightly called out other countries for failing to pay their fair share for medicines. Importing those same flawed policies into the U.S. would undermine our leadership at a time when China is poised to surpass us in medicine development."

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. PhRMA member companies have invested more than $850 billion in the search for new treatments and cures over the last decade, supporting nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.Innovation.org
www.VotersforCures.org
www.MAT.org
www.LinkedIn.com/Company/PhRMA
www.X.com/PhRMA